Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.

Theranostics · 2024 · PMC11024848 · PMID 38646643

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

The differences in tumor growth and survival outcomes between the combination and each monotherapy were highly significant.

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [&lt;sup&gt;177&lt;/sup&gt;Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.

The sentences

Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [<sup>177</sup>Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside.